Browse drugs

…ic effect of preoperative programmed death receptor-1 inhibitor pembrolizumab for treating non-small cell lung cancer (NSCLC). Herein, we rep…

…veloped a widespread, pruritic grade 3/4 eczematous reaction to pembrolizumab, significantly impacting his quality of life. Following cessati…

…after surgery, neoadjuvant nivolumab prior to surgery, adjuvant pembrolizumab and atezolizumab after surgery, perioperative durvalumab and pe…

…eloped cutaneous melanoma and underwent adjuvant treatment with pembrolizumab. The patient presented with a new choroidal lesion adjacent to …

…tatic lung adenocarcinoma receiving carboplatin, pemetrexed and pembrolizumab presented with subacute bilateral lower limb oedema and erythem…

…erapy –specifically those including pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezolizumab–, in the treatment …

…receiving durvalumab, 25% receiving cemiplimab, 66.7% receiving avelumab, and 60% receiving the ipilimumab and nivolumab. A 61.5% of irA…

…icity of MCC and the risk of renal complication associated with pembrolizumab, underscoring the need for vigilance in anticipating and preven…

…response (pCR) rates and survival outcomes with the addition of pembrolizumab to neoadjuvant chemotherapy. However, long-term immune-related …

…ted 76 164 life years gained. Only three accelerated approvals (nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung c…

… with treatment-naïve, stage IV NSQ NSCLC without AGAs received STK-012 subcutaneously (SC) Q3W + standard of care pembrolizumab, pemet…

…hemotherapy (HR=2.35; 95% CI:1.39–3.96) or pembrolizumab versus nivolumab (HR=2.46; 95%CI:1.13–5.36) ( figure 1) also conferred a higher …